Hormonal manipulation of benign prostatic hyperplasia.

Area of Science:

• Endocrinology
• Urology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Hormonal therapies play a crucial role in managing BPH.
• 5-alpha reductase inhibitors (5-ARIs) are established treatments.

Purpose of the Study:

• To review current understanding of hormonal control in BPH.
• To compare efficacy and safety of finasteride and dutasteride.
• To explore novel hormonal treatments for BPH.

Main Methods:

• Review of current literature on 5-ARIs (finasteride, dutasteride).
• Analysis of indications, efficacy, and safety data.
• Examination of preclinical data on new agents like GHRH and LHRH antagonists.

Main Results:

• Finasteride and dutasteride demonstrate comparable efficacy and safety for BPH treatment and prevention.
• 5-ARIs are recommended for larger prostates ( > 40ml) and elevated PSA ( > 1.5 ng/ml).
• Combination therapy offers no added benefit over 5-ARI monotherapy in specific patient subgroups (e.g., large prostate volume or high symptom score).
• Preclinical studies indicate GHRH and LHRH antagonists can reduce prostate volume.

Conclusions:

• New 5-ARIs represent promising therapeutic options requiring further investigation.
• GHRH and LHRH antagonists show potential for prostate volume reduction via direct prostatic receptor action.
• Adverse effects associated with 5-ARIs necessitate the exploration of alternative therapies.